PharVision Advisers’s Fulgent Genetics FLGT Stock Holding History

PharVision Advisers’s Portfolio FLGT Stock Details FLGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,951	Closed	-$209K	–	302
2025 Q4	$209K	Buy	+7,951	New	+$206K	0.11%	521

Other funds holding FLGT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

PharVision Advisers's FLGT Position: Q1 2026 in Review

PharVision Advisers sold out of Fulgent Genetics (FLGT) in Q1 2026, closing a stake of 7,951 shares — an estimated $209K sold.

PharVision Advisers first reported a position in FLGT in Q4 2025 and held it in 1 quarter. The position peaked at $209K in Q4 2025. 158 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

PharVision Advisers reported no remaining Fulgent Genetics position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 7,951 Fulgent Genetics shares in Q1 2026, an estimated $209K.
PharVision Advisers first reported a position in Fulgent Genetics in Q4 2025 and held it in 1 quarter.
PharVision Advisers's Fulgent Genetics position peaked at $209K in Q4 2025.
158 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.